Home
Drug Linked to Diabetic Ketoacidosis, Several Life-Threatening Side Effects
Invokana, the brand name for the drug canagliflozin, is designed to help control blood sugar levels in patients with type-2 diabetes. It is part of a class of medications referred to as SGLT2 (sodium-glucose cotransporter-2) inhibitors. In addition to Invokana, other drugs in this class include Invokamet, Glyxambi, Xigduo XR, Farxiga, and Jardiance. These drugs work to prevent high levels of blood sugar (a condition known as hyperglycemia) by assisting in the removal of excess sugar through urination.
However, the FDA issued a Safety Communication in May 2015 involving all SGLT2 inhibitors, warning they may cause diabetic ketoacidosis. The warning was issued after the agency received reports of 20 patients suffering from the condition after taking the medications. In September 2015, the FDA updated Invokana’s warning label to include information regarding a heightened risk for bone fractures as well as a reduction in bone density.
More here: http://www.marketwatch.com/story/baron-budd-investigating-potential-lawsuits-involving-diabetes-drug-invokana-2015-11-03
the money it will cost them if the lawsuits are successful is a trivial amount considering the vast profits they will have already made on made on the drug.
